Indeed, the anticancer drug sunitinib, a broad-spectrum receptor tyrosine kinase inhibitor, blocked progressive splenomegaly and improved immunity as adjuvant therapy in murine experimental leishmaniasis (66). This evidence concerns the gene NTRK1 and leishmaniasis.